Abbott Capitulates In Continuous Glucose Deal: Can SpectRx Go It Alone?

SpectRx likely will have to find another development partner for FDA pivotal studies of its consumer continuous glucose monitoring device after initiating termination of a joint R&D and license agreement with Abbott Laboratories Jan. 7